Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, AIDS-Related 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 2veliparib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1Taxes 1Specimen Handling 1Radiotherapy, Conformal 1Radiotherapy 1Radiosurgery 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Docetaxel 1Disulfides 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma, Bronchiolo-Alveolar × pegylated granulocyte colony-stimulating factor × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡